MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from draw down of
debt
$330,000K
Proceeds from issuance of
common stock upon...
$67,904K
Proceeds from issuance of
common stock upon...
$59,558K
Net cash provided by
financing activities
$101,465K
Canceled cashflow
$355,997K
Net increase
(decrease) in cash
$7,580K
Canceled cashflow
$93,885K
Repayment of debt
$331,988K
Payment of contingent
consideration
-$9,940K
Payments of tax
withholdings on stock awards
$7,110K
Payment of debt issuance
costs
$3,638K
Payments on principal
portion of finance lease...
$2,124K
Cash paid for common
stock issuance costs
$1,197K
Stock-based compensation
expense
$93,752K
Accrued expenses and
other current...
$83,743K
Loss on debt
extinguishment
-$10,385K
Amortization of intangible
asset
$6,375K
Non-cash lease expense
$3,046K
Right-of-use asset
amortization for finance...
$2,186K
Amortization of debt discount
$1,303K
Depreciation
$503K
Net cash used in
operating activities
-$93,405K
Net cash used in
investing activities
-$480K
Canceled cashflow
$201,293K
Net loss
-$183,174K
Purchases of equipment
$480K
Accounts receivable, net
$82,463K
Inventories, net
$10,660K
Accounts payable
-$6,460K
Non-current inventory and
other assets
$5,010K
Loss in fair value of
contingent consideration
-$2,473K
Gain from lease
modification
$2,250K
Prepaid expenses and
other current assets
$1,673K
Operating lease liability
-$535K
Revenue
$638,496K
Loss (gain) in fair
value of contingent...
-$2,473K
Profit Loss
-$183,174K
Canceled cashflow
$640,969K
Selling and marketing
expense (excluding...
$440,402K
Stock-based compensation
expense
$93,752K
General and
administrative expense...
$63,273K
Research and development
expense...
$55,312K
Cost of revenue
(excluding amortization...
$47,478K
Research and development
expense...
$42,106K
Research and development
expense...
$21,421K
Other research and
development
$20,645K
Other segment items
$16,230K
Research and development
expense...
$8,485K
Research and development
expense...
$8,482K
Interest expense, net
-$6,557K
Back
Back
Cash Flow
source: myfinsight.com
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)